Teva Pharmaceutical Industries (NYSE:TEVA) Upgraded at Wall Street Zen

Teva Pharmaceutical Industries (NYSE:TEVA) was upgraded by Wall Street Zen from a “buy” rating to a “strong-buy” rating in a report issued on Saturday.

TEVA has been the topic of a number of other reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research report on Wednesday, October 8th. Jefferies Financial Group raised their price target on Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the stock a “buy” rating in a research report on Tuesday. Barclays initiated coverage on Teva Pharmaceutical Industries in a research report on Tuesday, December 9th. They issued an “overweight” rating and a $35.00 price objective for the company. The Goldman Sachs Group increased their price objective on shares of Teva Pharmaceutical Industries from $31.00 to $35.00 and gave the stock a “buy” rating in a research report on Friday, December 19th. Finally, Piper Sandler increased their target price on Teva Pharmaceutical Industries from $30.00 to $40.00 and gave the stock an “overweight” rating in a report on Monday, December 22nd. Three research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Teva Pharmaceutical Industries currently has an average rating of “Buy” and an average price target of $33.67.

Teva Pharmaceutical Industries Stock Down 1.5%

Shares of NYSE TEVA opened at $32.03 on Friday. The company has a current ratio of 1.11, a quick ratio of 0.82 and a debt-to-equity ratio of 2.31. The firm has a market capitalization of $36.73 billion, a PE ratio of 53.38, a price-to-earnings-growth ratio of 1.88 and a beta of 0.66. The firm’s 50-day moving average is $28.04 and its 200-day moving average is $21.53. Teva Pharmaceutical Industries has a 1 year low of $12.47 and a 1 year high of $32.91.

Insider Activity

In related news, CAO Amir Weiss sold 12,300 shares of the stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $30.20, for a total value of $371,460.00. Following the sale, the chief accounting officer owned 5,650 shares in the company, valued at approximately $170,630. This represents a 68.52% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Richard Daniell sold 115,468 shares of the firm’s stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $28.68, for a total value of $3,311,622.24. Following the sale, the vice president directly owned 48,384 shares of the company’s stock, valued at $1,387,653.12. This represents a 70.47% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 622,060 shares of company stock worth $17,076,965. Insiders own 0.49% of the company’s stock.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

Large investors have recently modified their holdings of the stock. Wealth Enhancement Advisory Services LLC boosted its holdings in shares of Teva Pharmaceutical Industries by 3.3% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 11,911 shares of the company’s stock worth $382,000 after buying an additional 379 shares during the period. Howard Bailey Securities LLC lifted its position in Teva Pharmaceutical Industries by 3.5% during the third quarter. Howard Bailey Securities LLC now owns 14,451 shares of the company’s stock worth $292,000 after acquiring an additional 494 shares during the last quarter. ASR Vermogensbeheer N.V. boosted its holdings in shares of Teva Pharmaceutical Industries by 1.6% during the third quarter. ASR Vermogensbeheer N.V. now owns 31,915 shares of the company’s stock worth $645,000 after acquiring an additional 515 shares during the period. CIBC Private Wealth Group LLC grew its position in shares of Teva Pharmaceutical Industries by 15.5% in the third quarter. CIBC Private Wealth Group LLC now owns 4,020 shares of the company’s stock valued at $81,000 after purchasing an additional 540 shares during the last quarter. Finally, Retirement Planning Co of New England Inc. grew its position in shares of Teva Pharmaceutical Industries by 1.8% in the third quarter. Retirement Planning Co of New England Inc. now owns 33,230 shares of the company’s stock valued at $671,000 after purchasing an additional 588 shares during the last quarter. 54.05% of the stock is owned by institutional investors.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.